Tareq Abadl: The Hidden Danger in a Blood Bag – When a Unit Looks ‘Wrong’
Tareq Abadl, Medical Lab Specialist, shared a post on LinkedIn:
“The Hidden Danger in a Blood Bag: When a Unit Looks ‘Wrong’
Did you know that if a blood bag contains visible clots or fibrin strands, it should not be transfused?
Many people think transfusion safety is only about ABO, Rh, and antibody testing — but sometimes the warning sign is something you can actually see with the naked eye.
Blood components are collected into bags containing anticoagulants to prevent clotting. However, clotting activation can still occasionally occur, leading to the formation of:
- Clots
- Fibrin strands
- Clumps or aggregates
- Abnormal discoloration or appearance
Why is this important?
Because visible clots or fibrin strands may indicate:
- Activation of the coagulation process
- Product quality deterioration
- Improper storage or handling
- Potential risk to the patient if transfused
That is why blood-bank personnel and transfusion services perform careful visual inspection before releasing blood products.
A unit may be rejected even if:
- The blood type is correct
- Compatibility testing is acceptable
- The label appears normal
If unusual findings are seen, the component should be:
- Returned to the transfusion service
- Investigated further
- Withheld from transfusion until deemed safe
Another important laboratory point:
Different blood components can show different abnormal appearances.
For example:
- RBC units can show clots, hemolysis, dark discoloration
- Plasma can show unusual turbidity or color change
- Platelets can show clumping or loss of the normal swirling appearance
This is one of the most fascinating parts of medical laboratory science in transfusion medicine:
Blood-bank safety is not only about compatibility testing — it also includes visual inspection, storage monitoring, quality control, and product release safety.”
Other posts featuring Tareq Abadl on Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke